FDA approves UCB’s Briviact
SILVER SPRING, Md. — The Food and Drug Administration on Friday approved Briviact (brivaracetam) from Smyrna, Ga.-based UCB. The drug is indicated as an add-on treatment to other medication for partial onset seizures in patients with epilepsy aged 16 years and older.
“Patients can have different responses to the various seizure medicines that are available,” said Dr. Billy Dunn, director of the Division of Neurology Products in the FDA's Center for Drug Evaluation and Research. “With the approval of Briviact, I am pleased that patients with epilepsy have a new treatment option.”
The drug must be dispensed with a patient medication guide that explains information about using Briviact and its potential risks, including thoughts of suicide, feelings of agitation, suicide attempts, depression that is new or worsens, aggression and panic attacks.
BoozAid hits market with anti-flush, anti-hangover supplement
SAN MATEO, Calif. – BoozAid recently announced the introduction of its anti-flush and anti-hangover remedy to market.
According to the company, more than half the population of Asian descent suffer from a condition known as alcohol flush syndrome. After a few sips of alcohol, those who suffer from alcohol flush experience extreme heart palpitations, dizziness, nausea and total body itching. It causes one's eyes and face to turn red-and there also may be blotchy red patches on the body.
The primary cause of alcohol flush is the inability to metabolize alcohol efficiently. This is because certain individuals don't have the liver enzyme ALDH2 used by the body to properly break down alcohol.
BoozAid capsules are formulated with 12 natural ingredients, including dihydromyricetin, an ingredient extracted from the Holvenia plant that is proven to rid the liver of alcohol by-products.
To avoid alcohol flush, two BoozAid capsules should be taken with 8 ounces of water 45 minutes prior to drinking; to avoid hangovers, two BoozAid capsules should be taken with 8 ounces of water before bedtime.
Loading Post Please Wait...